LDFR
VKTX icon

Lehman & Derafelo Financial Resources’s Viking Therapeutics VKTX Stock Holding History

Lehman & Derafelo Financial Resources’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,050
Closed -$18K – 272
2020
Q3 		$18K Hold
3,050
– – 0.01% 209
2020
Q2 		$22K Buy
+3,050
New +$20.3K 0.01% 185

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Lehman & Derafelo Financial Resources's VKTX Position: Q4 2020 in Review

Lehman & Derafelo Financial Resources sold out of Viking Therapeutics (VKTX) in Q4 2020, closing a stake of 3,050 shares — an estimated $18K sold.

Lehman & Derafelo Financial Resources first reported a position in VKTX in Q2 2020 and held it in 2 quarters. The position peaked at $22K in Q2 2020. 143 funds tracked by Wall St. Rank hold VKTX as of Q4 2020.

  • Lehman & Derafelo Financial Resources reported no remaining Viking Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Lehman & Derafelo Financial Resources sold 3,050 Viking Therapeutics shares in Q4 2020, an estimated $18K.
  • Lehman & Derafelo Financial Resources first reported a position in Viking Therapeutics in Q2 2020 and held it in 2 quarters.
  • Lehman & Derafelo Financial Resources's Viking Therapeutics position peaked at $22K in Q2 2020.
  • 143 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2020.

Based on Lehman & Derafelo Financial Resources's 13F filing for Q4 2020, filed 20 Jan 2021.